Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection
Bhagyashri D Navalkele,1 Teena Chopra2 1Internal Medicine and Infectious Diseases, University of Mississippi Medical Center, Jackson, MS, USA; 2Internal Medicine and Infectious Diseases, Infection Prevention and Epidemiology, Detroit Medical Center, Wayne State University, Detroit, MI, USA Abstract...
Guardado en:
Autores principales: | Navalkele BD, Chopra T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eaf6898b1e0b4043beebc88d4c927468 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Characteristics, Risk Factors, and Prevalence of Clostridioides difficile Among Hospitalized Patients in a Tertiary Care Hospital in Palestine
por: Abukhalil AD, et al.
Publicado: (2021) -
Genetic Association Reveals Protection against Recurrence of <italic toggle="yes">Clostridium difficile</italic> Infection with Bezlotoxumab Treatment
por: Judong Shen, et al.
Publicado: (2020) -
Current strategies for diagnosis and treatment of Clostridium difficile-infection (literature review)
por: I. V. Nikolaeva, et al.
Publicado: (2018) -
Abordaje multidisciplinario de la infección por Clostridium difficile
por: Pérez,Marta, et al.
Publicado: (2013) -
Colitis fulminante asociada a Clostridium difficile
por: BANNURA C,GUILLERMO, et al.
Publicado: (2012)